Technology area: Biotechnology & Pharmaceuticals
53 pending office actions • 34 clients • 51 examiners • 44 art units • 0 of 53 (0%) have an AI response strategy ready
Umberg Zipser, LLP reports 53 pending office actions in Biotechnology & Pharmaceuticals and 1862 career applications. The pending docket is presented alongside a sizable reported application record, providing context for the firm’s active prosecution workload.
The resolved allowance rate is 80.57%, and the average is 3.28 office actions per allowance. The latter measure indicates repeated examination activity in resolved matters, while the allowance figure describes the reported rate at which those matters reached allowance.
This combination gives practitioners a basis for evaluating both scale and prosecution demands. The application total frames the historical portfolio, and the outcome measures can inform expectations about claim development, response cycles, and the work required to pursue allowance.
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 11 (21%) |
| §103 only | 15 (28%) |
| §102 only | 3 (6%) |
| §112 only | 3 (6%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 3 (6%) |
| Multi-statute (no §101) | 15 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, GUOZHEN | 2 | 48.1% | +26.0% |
| ZEMAN, MARY K | 2 | 58.9% | +34.2% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| HANSEN, JARED A | 1 | 53.1% | +48.0% |
| PAULS, JOHN A | 1 | 49.0% | +27.7% |
| PARK, SOO JIN | 1 | 82.0% | +17.2% |
| TAMIL, JESSICA KAVINI | 1 | 39.4% | +46.0% |
| ARANT, HARRY E | 1 | 50.0% | +21.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19067041 | Method For Predicting Volume Of Object Based On Whether Object In Container Changes | PARK, SOO JIN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280778 | Multi-Dose Container for Ophthalmic Compositions | FAY, ZOHREH ALEMZADEH | 119d overdue |
| 18292702 | Method And Device For Detecting Multi-Access Account By Using Similarity Degree Between Nicknames | RENWICK, REGINALD A | 31d overdue |
| 18876659 | Improvements In Or Relating To Data Integrity | PUTTAIAH, ASHA | 25d overdue |
| 18782979 | Arthroscopic Surgery System And Method | LABRANCHE, BROOKE N | 1d overdue |
| 17850756 | METHODS FOR FORECASTING CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA USING RNA-BASED BIOMARKERS AND MACHINE LEARNING ALGORITHMS | SMITH, JENNIFER JOY | 9d |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 16d |
| 19061787 | Collapsible Container | TAMIL, JESSICA KAVINI | 27d |
| 19047205 | Compositions and Methods to Form a Thermally Conductive Sheath | ARANT, HARRY E | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16222798 | Systems and Methods For RNA Analysis In Functional Confirmation Of Cancer Mutations | ZEMAN, MARY K | 77d overdue |
| 19061787 | Collapsible Container | TAMIL, JESSICA KAVINI | 27d |
| 19047205 | Compositions and Methods to Form a Thermally Conductive Sheath | ARANT, HARRY E | 34d |
| 19460222 | STABLE COMPOSITIONS OF BUPIVACAINE HYDROCHLORIDE | ELENISTE, PIERRE PAUL | — |
| 19454185 | haNK Cetuximab Combinations And Methods | GODDARD, LAURA B | — |
| 19447763 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | DUFFY, BRADLEY | — |
| 19411048 | Prismatic Battery Cell and Method of Making the Same | HANSEN, JARED A | — |
| 19288633 | Systems and Methods for Detecting and Documenting Cryogenic Therapy of a Patient | PAULS, JOHN A | — |
| Art Unit | Apps |
|---|---|
| 1686 | 4 |
| 1644 | 3 |
| 1642 | 2 |
| 1685 | 2 |
| 1622 | 1 |
| 1643 | 1 |
| 1723 | 1 |
| 3683 | 1 |
| 3733 | 1 |
| 3763 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19460222 | STABLE COMPOSITIONS OF BUPIVACAINE HYDROCHLORIDE | Nevakar Injectables Inc. | ELENISTE, PIERRE PAUL | 1622 | §103 | Final Rejection | — | Pending | Jan 26, 2026 |
| 19454185 | haNK Cetuximab Combinations And Methods | Nantcell, Inc. | GODDARD, LAURA B | 1642 | DP | Final Rejection | — | Pending | Jan 20, 2026 |
| 19447763 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | Albunext, LLC | DUFFY, BRADLEY | 1643 | DP | Non-Final OA | — | Pending | Jan 13, 2026 |
| 19411048 | Prismatic Battery Cell and Method of Making the Same | Nantg Power, LLC | HANSEN, JARED A | 1723 | §103 | Final Rejection | — | Pending | Dec 05, 2025 |
| 19288633 | Systems and Methods for Detecting and Documenting Cryogenic Therapy of a Patient | Katherine Bao-Shian Lee Md, Apc | PAULS, JOHN A | 3683 | §101§103 | Non-Final OA | — | Pending | Aug 01, 2025 |
| 19067041 | Method For Predicting Volume Of Object Based On Whether Object In Container Changes | Nuvilabs Co., Ltd. | PARK, SOO JIN | §102 | Non-Final OA | — | Pending | Feb 28, 2025 | |
| 19061787 | Collapsible Container | Clevermade, LLC | TAMIL, JESSICA KAVINI | 3733 | §103§112 | Final Rejection | 27d | Pending | Feb 24, 2025 |
| 19047205 | Compositions and Methods to Form a Thermally Conductive Sheath | Xgs Energy, Inc. | ARANT, HARRY E | 3763 | §102§103 | Final Rejection | 34d | Pending | Feb 06, 2025 |
| 19046406 | Method For Predicting Volume Of Target Object Using Reference Object | Nuvilabs Co., Ltd. | RHIM, WOO CHUL | 2676 | §102§103 | Non-Final OA | — | Pending | Feb 05, 2025 |
| 18876659 | Improvements In Or Relating To Data Integrity | Tokencertify Limited | PUTTAIAH, ASHA | 3691 | §101§103 | Final Rejection | 25d overdue | Pending | Dec 18, 2024 |
| 18868726 | Surgical Assembly and System | Alesi Surgical Limited | OUYANG, BO | 3794 | §103 | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18882219 | Nant COVID Vaccine Cross Reactivity | Immunitybio, Inc. | WANG, RUIXUE | 1672 | §102§103§112Other | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18820045 | Methods And Systems For Producing Carbon-Neutral Fuels From Aragonite | Calcean Minerals And Materials, LLC | JEONG, YOUNGSUL | 1772 | §112Other | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18782979 | Arthroscopic Surgery System And Method | Convergence Medical Pty Ltd. | LABRANCHE, BROOKE N | 3771 | §102§103§112 | Final Rejection | 1d overdue | Pending | Jul 24, 2024 |
| 18769216 | Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi Cells | Nantbio, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18715883 | UV SYSTEM AND METHODS FOR GENERATING AN ALPHA CHANNEL | The Invisible Pixel Inc. | BOYLAN, JAMES T | 2486 | §103 | Non-Final OA | 15d overdue | Pending | Jun 03, 2024 |
| 18713607 | NEW CRYSTAL FORM OF COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | E-Nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | LEE, CHIHYI NMN | §112 | Non-Final OA | — | Pending | May 24, 2024 | |
| 18671662 | Primary T-Cell Expansion | Nantbio, Inc. | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | — | Pending | May 22, 2024 |
| 18710969 | Optical Coupling Structure | Ligentec SA | CHU, CHRIS H | 2874 | §102§103 | Final Rejection | — | Pending | May 16, 2024 |
| 18643905 | Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment | Nantbio, Inc. | WOOLWINE, SAMUEL C | 1681 | §103 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | Nant Holdings Ip, LLC | ATKINSON, JOSHUA ALEXANDER | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18693129 | COMPOSITION AND COMPOSITE ARTICLE FOR FORMING NITRIC OXIDE | Sterile State, Inc. | CHEN, CHANGRU | 1796 | §102§103 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18606693 | BIO-RESORBABLE ORTHOPAEDIC LAG SCREW FOR SMALL BONE FRACTURE FIXATION | Biocomposites Limited | COLEY, ZADE JAMES | 3775 | §102§103 | Final Rejection | — | Pending | Mar 15, 2024 |
| 18594178 | Chlorthalidone Compositions And Methods | Nivagen Pharmaceuticals, Inc. | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Non-Final OA | 40d | Pending | Mar 04, 2024 |
| 18292702 | Method And Device For Detecting Multi-Access Account By Using Similarity Degree Between Nicknames | Kakao Games Corp. | RENWICK, REGINALD A | 3715 | §101 | Final Rejection | 31d overdue | Pending | Jan 26, 2024 |
| 18292864 | Method And Device For User Information Prediction Using Play Log | Kakao Games Corp. | WASAFF, JOHN S. | 3629 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18573680 | Method For Providing Dart Game And Dart Game Server | Phoenixdarts Co., Ltd. | VANDERVEEN, JEFFREY S | 3711 | §103 | Final Rejection | 15d | Pending | Dec 22, 2023 |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | Immunitybio, Inc. | PETRASH, HILARY ANN | 1644 | §102§103§112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18497318 | Method For Predicting Protein Binding Site | Deargen Inc. | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18555493 | Organic Compound And Organic Light Emitting Device Including Same | P&H Tech Co., Ltd. | MOWLA, GOLAM | 1721 | §102 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18474797 | Cancer Score for Assessment and Response Prediction from Biological Fluids | Nantomics LLC | LIU, GUOZHEN | 1686 | §101§103§112Other | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18465868 | Cancer Score for Assessment and Response Prediction from Biological Fluids | Nantomics, LLC | LIU, GUOZHEN | 1686 | §101§103§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18280778 | Multi-Dose Container for Ophthalmic Compositions | Vyluma Inc. | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Non-Final OA | 119d overdue | Pending | Sep 07, 2023 |
| 18272533 | Devices and Methods for Providing Nitric Oxide | Sterile State, Inc. | TAI, XIUYU | 1795 | §102§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18272541 | Devices and Methods for Detecting the Presence of Nitric Oxide | Sterile State, Inc. | EOM, ROBERT J | 1797 | §102 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18343065 | Method For Change Detection | Si Analytics Co., Ltd. | LEE, BENEDICT E | 2665 | §103 | Final Rejection | — | Pending | Jun 28, 2023 |
| 18258925 | Fc-Receptor CAR Constructs and Cells | Immunitybio, Inc. | MELCHIOR, JAMES RYLAND | 1644 | §103§112 | Final Rejection | 54d | Pending | Jun 22, 2023 |
| 18038934 | Optical Device Having Monolithic Architecture And Method For Manufacturing Same | Deep-In-Sight Co., Ltd. | BAGHDASARYAN, HOVHANNES | 3645 | §103 | Final Rejection | 16d overdue | Pending | May 25, 2023 |
| 18043276 | Genetic Construct | Instituto De Medicina Molecular João Lobo Antunes | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | 40d | Pending | Feb 27, 2023 |
| 18164423 | Gate Operator with Context Sensitive QR Code | Intelligent Entry Machines LLC | PAN, YONGJIA | 2118 | §103 | Final Rejection | — | Pending | Feb 03, 2023 |
| 17999087 | T Cells | Instituto De Medicina Molecular João Lobo Antunes | WESTON, ALYSSA G | 1633 | §102§103§112 | Non-Final OA | — | Pending | Nov 17, 2022 |
| 17850756 | METHODS FOR FORECASTING CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA USING RNA-BASED BIOMARKERS AND MACHINE LEARNING ALGORITHMS | Genomic Testing Cooperative, Lca | SMITH, JENNIFER JOY | 1685 | §101§103§112 | Final Rejection | 9d | Pending | Jun 27, 2022 |
| 17739792 | Systems, Methods, and Compositions for Viral-Associated Tumors | Five3 Genomics, LLC | ZEMAN, MARY K | 1686 | §101§102Other | Non-Final OA | — | Pending | May 09, 2022 |
| 17740040 | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | Nant Holdings Ip, LLC | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112DP | Non-Final OA | — | Pending | May 09, 2022 |
| 17720624 | Compositions and Methods for Targeted NGS Sequencing of cfRNA and cfTNA | Genomic Testing Cooperative, Lca | POHNERT, STEVEN C | 1683 | §101§103§112 | Final Rejection | — | Pending | Apr 14, 2022 |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | Immunitybio, Inc. | LIN, JERRY | 1685 | §101§103 | Final Rejection | 16d | Pending | Apr 08, 2022 |
| 17697781 | Techniques For Performing Subject Word Classification Of Document Data | Tmaxtibero Co., Ltd. | OPSASNICK, MICHAEL N | 2658 | §102§103 | Non-Final OA | 72d | Pending | Mar 17, 2022 |
| 17631844 | Metal Recovery From Lead Containing Electrolytes | Aqua Metals Inc. | WILKINS III, HARRY D | 1794 | §103 | Final Rejection | — | Pending | Jan 31, 2022 |
| 17630075 | ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS | Immunitybio, Inc. | LU, CHENG | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 25, 2022 |
| 17270361 | Neural Interface | University Of Maribor | PORTILLO, JAIRO H | 3791 | §103 | Non-Final OA | — | Pending | Feb 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial80.6% of resolved applications prosecuted by Umberg Zipser LLP were allowed, across 1,862 applications in USPTO records.
3.28 office actions per allowed application on average.
53 pending office actions as of October 2026, for 34 clients, before 51 examiners in 44 art units.
